Search

Myeloid sarcoma is a rare tumour composed of immature myeloid cells. Its occurrence in childhood is rare. Only a few cases of intraoral myeloid sarcoma have been reported in literature. We present a case of myeloid sarcoma with simultaneous involvement of intraoral soft tissues and lymph node. Here, importance is given to suspect this frequently misdiagnosed disease.

Copyright of Ginecología y Obstetricia de México is the property of Federacion Mexicana de Ginecologia y Obstetricia and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Non-hodgkin lymphoma (NHL) are rare tumors of the jaws. their locations in the air spaces of the face coming in second row. We related the case of a primitive NHL located in the maxillary sinus in a patient of 47 years, which illustrates the diagnostic difficulties encountered face a little suggestive symptoms. The diagnosis was confirmed by histological examination. The evolution was favorable after medical treatment based chemotherapy combined with versatile external radiotherapy. From this observation, we will review the literature in order to review the clinical, radiological, histological, therapeutic and outcome of this rare disease. [ABSTRACT FROM AUTHOR]

Lymphoma is generally a nodal disease and arises from lymphoid tissues or organs. Extranodal lymphoma accounts for almost a third of malignant lymphomas. Squamous cell carcinoma accounts for 90% of laryngeal carcinoma, while extranodal Non Hodgkin Lymphoma (NHL) attributes only less than 1% of laryngeal neoplasms. Less than 100 of such cases been reported in literature since 1952. As to our best knowledge, no such case was ever reported in our country. We report a case of a 58-year-old gentleman who presented the typical history of laryngeal malignancy however the pathology turned out to be as NHLof Diffuse Large B-cell subtype. [ABSTRACT FROM AUTHOR]

The aim of this study is to evaluate the basic epidemiological and clinical characteristics of lymphoma in childhood at the Department of Hematooncology, Pediatric Clinic, Clinical Center University of Sarajevo (CCUS), in ten year period. Patients and Methods: the study included 58 patients, of both gender, aged 0-15 years, diagnosed with lymphoma at the Department of Hematooncology, Pediatric Clinic of CCUS, in the period from January 1st 2004 to December 31st 2013. The retrospective study of patients with lymphoma in childhood was conducted. The results were presented using tables and charts, with number of cases and percentages. Statistical analysis of significant differences was performed using Fisher and Chi-square test. The values of p<0.05 or on the level reliability of 95% were considered statistically significant. Results: our study included 58 patients, 37 (63.80%) boys and 21 (36.20%) girls. Most of the patients were in the age group of 8-15 years, namely 38 (65.50%) patients. The leading symptom of lymphoma in childhood was lymphadenopathy, which was presented in 45 (77.58%) patients, followed by subfebrile temperature in 19 (32.75%), paleness in 16 (27.59%), hepatosplenomegaly in 13 (22.41%), and weight loss in 12 (20.69%) patients. The following elevated values were noted: LDH in 16 patients with HL and 14 with NHL, and Cu in 15 patients with HL and 10 with NHL. Majority of the patients with HL were diagnosed in stage II of disease, 12 (37.50%) patients, and 11 (34.40%) in stage IV. Majority of patients with NHL were diagnosed in stage II, 13 (50%), and 8 (30.80%) in stage IV. Conclusion: clinical diagnostic methods and modern therapy at the Pediatric Clinic of CCUS contribute to good prognosis for patients suffering from lymphoma in childhood. [ABSTRACT FROM AUTHOR]

Introduction: lymphomas are the primary neoplasias of the lymphatic system, which are usually manifested by painless enlargement of the lymph nodes. In children, the third most common malignancy are lymphomas, after leukemias and brain tumors. They represent 10-13% of newfound malignancies in children. There has been progress in the last 20 years as a diagnostic as well as therapeutic. Despite the progress of genetics, molecular biology and immunology, and their significant results, causes of these diseases have not yet been identified. Aim: the aim of this study is to evaluate the basic epidemiological and clinical characteristics of childhood lymphoma at the Hematooncology Department of Pediatric Clinic of the Sarajevo University Clinical Center (CCUS) in a ten year period. Patients and methods: the study included 58 patients, of both gender, aged 0 through 15, with diagnosis of lymphoma at the Hematooncology Department of the Pediatric Clinic of CCUS, during the period from January 1st 2004 to December 31st 2013. The retrospective study of patients with lymphoma in childhood was conducted. The results were presented using tables and charts, with number of cases and percentages. Statistical analysis of significant differences was performed using Fisher and Chi - square test. The values of p<0.05 or on the level reliability of 95% were considered statistically significant. Results: our study included 58 patients, 37 (63.80%) boys and 21 (36.20%) girls. It showed a higher percentage prevalence of boys compared to girls. Most patients were in the age group of 8-15 years, 38 (65.50%) patients. The leading symptom of lymphoma in childhood was lymphadenopathy, which was presented in 45 (77.58%) patients, followed by subfebrile temperature in 19 (32.75%), paleness in 16 (27.59%), hepatosplenomegaly in 13 (22.41%), and weight loss in 12 (20.69%) patients. The following elevated values were noted: LDH in 16 patients with HL and 14 with NHL, and Cu in 15 patients with HL and 10 with NHL. Most patients with HL were diagnosed in stage II of disease, 12 (37.50%) patients, and 11 (34.40%) in stage IV. Most patients with NHL were diagnosed in stage II, 13 (50%), and 8 (30.80%) in the IV stage. After leukemias (157 patients - 39.20%), lymphomas were the second malignancies in children, represented with 14.50% of all malignancies diagnosed at the Pediatric Clinic. Each year, an average 5.8 of new cases has ocurred and majority of them (10 new cases) in 2013. Ten-year survival of patients with HL was 87.50% and 80.77% with NHL. Conclusion: lymphomas are the second malignancies in children at the Pediatric Clinic of CCUS. Most patients are in the age group of 8-15 years, with higher percentage prevalence of boys compared to girls. Clinical diagnostic methods and modern therapy at the Pediatric Clinic contribute to the good prognosis for patients suffering from lymphoma in childhood. The survival rates of patients are similar to those in the international centres. [ABSTRACT FROM AUTHOR]

Nasal type NK/T-cell lymphoma is a rare type of predominantly extranodal non-Hodgkin lymphoma. Early and correct diagnosis with prompt treatment of NK/T-cell lymphoma is important in view of its potentially aggressive behavior and poor response to treatment with additional sites of tumor developing sometimes weeks or months after initial diagnosis. Unfortunately diagnosis of NK/T-cell lymphomas often proves difficult. The diagnosis is essentially based on the clinical presentation of extranodal ulcerative lesions in the upper aero-digestive tract and histopathologic analysis of biopsies using immunohistochemistry. Here we present two cases with nasal-type NK/T-cell lymphoma that illustrate that definitive diagnosis is often delayed due to the atypical initial presentation. We will discuss the pitfalls in diagnosing this rare type of neoplasm and review the treatment options. [ABSTRACT FROM AUTHOR]

Hematologic malignancies, including multiple myeloma (MM], will account for more than 1OO,OOO new cases of cancer and over 57,000 deaths in the United States in 2003. Treatment of MM is a serious challenge, because despite a variety of available therapies, median survival is short. A new therapeutic area focuses on inhibiting the activity of the proteasome, a 26S protease complex involved in cell cycle regulation, cell adhesion, inflammation, and protein turnover. The novel proteasome inhibitor, 5ortezomi5 (Velcade®), was recently approved for use in patients with refractory and relapsed MM and to date is the only proteasome inhibitor to have entered clinical trials. Borte- zomib has demonstrated activity with manageable toxicity in a variety of hematologic malignancies in addition to MM, including leukemia and non-Hodgkin's lymphoma. This article reviews clinical information on bortezomib in hematologic malignancies both as monotherapy and in combination with dexamethasone. Preliminary reports of bortezomib in combination with Doxil (pegylated liposomal doxorubicin), melphalan, and thalidomide arc discussed, and current trials arc described. Available data suggest that bortezomib will be useful in the treatment of a variety of hematologic malignancies. [ABSTRACT FROM AUTHOR]

Paranasal sinus lymphoma is an uncommon malignancy and is often difficult to diagnose. Early diagnosis is essential for effective treatment. The tumour generally has poor prognosis. Ophthalmological symptoms and signs occur early in the disease process due to the close proximity of the orbit to the paranasal sinuses. Common presenting features include eye pain, proptosis, visual loss and diplopia. We report a case of frontal sinus lymphoma that presented as a superior-nasal orbital mass in an 84 year old man. CT scan demonstrated a mass occupying the frontal sinuses, with destruction of the anterior bony wall of the frontal sinus and extending to the right orbit. Histology revealed diffuse large B cell non Hodgkin's lymphoma. The tumor was treated with radiotherapy and showed regression; however the patient died 9 months later. Sinus tumours are encountered by ophthalmologists and should be considered in patients presenting with an orbital mass. [ABSTRACT FROM AUTHOR]